GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Innovent Biologics Inc (HKSE:01801) » Definitions » PS Ratio

Innovent Biologics (HKSE:01801) PS Ratio : 9.01 (As of Apr. 26, 2024)


View and export this data going back to 2018. Start your Free Trial

What is Innovent Biologics PS Ratio?

The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, Innovent Biologics's share price is HK$39.15. Innovent Biologics's Revenue per Share for the trailing twelve months (TTM) ended in Jun. 2023 was HK$4.35. Hence, Innovent Biologics's PS Ratio for today is 9.01.

The historical rank and industry rank for Innovent Biologics's PS Ratio or its related term are showing as below:

HKSE:01801' s PS Ratio Range Over the Past 10 Years
Min: 5.19   Med: 22.75   Max: 1115
Current: 9.13

During the past 8 years, Innovent Biologics's highest PS Ratio was 1115.00. The lowest was 5.19. And the median was 22.75.

HKSE:01801's PS Ratio is ranked worse than
51.06% of 993 companies
in the Biotechnology industry
Industry Median: 8.92 vs HKSE:01801: 9.13

Innovent Biologics's Revenue per Sharefor the six months ended in Jun. 2023 was HK$1.93. Its Revenue per Share for the trailing twelve months (TTM) ended in Jun. 2023 was HK$4.35.

Warning Sign:

Innovent Biologics Inc revenue per share is in decline over the past 12 months.

During the past 12 months, the average Revenue per Share Growth Rate of Innovent Biologics was -3.00% per year. During the past 3 years, the average Revenue per Share Growth Rate was 51.10% per year. During the past 5 years, the average Revenue per Share Growth Rate was 223.40% per year.

During the past 8 years, Innovent Biologics's highest 3-Year average Revenue per Share Growth Rate was 451.70% per year. The lowest was 51.10% per year. And the median was 382.40% per year.

Back to Basics: PS Ratio


Innovent Biologics PS Ratio Historical Data

The historical data trend for Innovent Biologics's PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Innovent Biologics PS Ratio Chart

Innovent Biologics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
PS Ratio
Get a 7-Day Free Trial 26.82 24.66 13.43 9.81 9.82

Innovent Biologics Semi-Annual Data
Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 13.43 - 9.81 - -

Competitive Comparison of Innovent Biologics's PS Ratio

For the Biotechnology subindustry, Innovent Biologics's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Innovent Biologics's PS Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Innovent Biologics's PS Ratio distribution charts can be found below:

* The bar in red indicates where Innovent Biologics's PS Ratio falls into.



Innovent Biologics PS Ratio Calculation

The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.

Innovent Biologics's PS Ratio for today is calculated as

PS Ratio=Share Price/Revenue per Share (TTM)
=39.15/4.345
=9.01

Innovent Biologics's Share Price of today is HK$39.15.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Innovent Biologics's Revenue per Share for the trailing twelve months (TTM) ended in Jun. 2023 was HK$4.35.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

PS Ratio=Market Cap/Revenue

The Revenue here is for the trailing 12 months.


Innovent Biologics  (HKSE:01801) PS Ratio Explanation

The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.

When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.

Similar to the PE Ratio or Price-to-Operating-Cash-Flow or Price-to-Free-Cash-Flow , the PS Ratio measures the valuation based on the earning power of the company. This is where it is different from the PB Ratio , which measures the valuation based on the company's balance sheet.


Be Aware

The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.


Innovent Biologics PS Ratio Related Terms

Thank you for viewing the detailed overview of Innovent Biologics's PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Innovent Biologics (HKSE:01801) Business Description

Traded in Other Exchanges
Address
168 Dongping Street, Suzhou Industrial Park, Jiangsu, Suzhou, CHN, 215123
Innovent Biologics, or Innovent, is one of the leading biotechnology companies in China. Listed on the Hong Kong Exchange in 2018, Innovent has eight commercialized oncology products and two commercialized non-oncology products as of August 2023. Its core asset is Tyvyt, a PD-1 inhibitor included in the National Reimbursement Drug Lists for the first-line treatment of five major cancers. Innovent has over 30 strategic collaborations with global pharmaceutical or biotech companies, such as Eli Lilly, Roche Group, Incyte, and others. It also has a wide spectrum of therapeutic targets in early clinical developments. Among its upcoming pipelines, the potential blockbuster is Mazdutide, a therapy for obesity and type 2 diabetes.

Innovent Biologics (HKSE:01801) Headlines

No Headlines